Mocertatug rezetecan is starting its first western pivotal trials.
ApexOnco Front Page
Recent articles
The holiday period included Genmab’s discontinuation of acasunlimab.
A deal with Jacobio is worth $100m up front.
Nenocorilant features among the latest industry projects newly into phase 1.
Two new PD-(L)1 x VEGF projects have entered the clinic.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
The private ADC company is being wound down.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
